EXPLORING SYNERGISTIC EFFECTS OF COMBINED DARATUMUMAB AND BELANTAMAB MAFODOTIN THERAPY IN MULTIPLE MYELOMA

EHA Library, Mauro Lorenzo-Mohamed, 420040

UMA PANEL: AN NGS APPROACH TO DEFINE THE MOLECULAR PROFILE OF MULTIPLE MYELOMA PATIENTS. RESULTS OF INTRA- AND INTER-LABORATORY VALIDATION EXPERIMENTS.

EHA Library, BARBARA TAURISANO, 420043

SOLUBLE BCMA AND BCMA-CONTENT IN CIRCULATING EXTRACELLULAR VESICLES TO EVALUATE RESPONSE IN MULTIPLE MYELOMA RECEIVING BCMA-DIRECTED CARTS

EHA Library, Bárbara Castellanos, 420044

EFFICACY AND SAFETY OF TALQUETAMAB, A GPRC5D×CD3 BISPECIFIC ANTIBODY, IN CHINESE PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA FROM THE PHASE 1/2 MONUMENTAL-1 STUDY

EHA Library, Jie Jin, 420047

PERCUTANEOUS VERTEBROPLASTY/KYPHOPLASTY CONTRIBUTES TO THE IMPROVED OUTCOME IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA: A SINGLE-CENTER COHORT STUDY.

EHA Library, Fujing Zhang, 420050

EVALUATION OF CHROMOSOMAL ABNORMALITIES AND OUTCOME IN A REAL WORLD POPULATION OF MYELOMA PATIENTS TREATED OVER 10 YEARS.

EHA Library, Thomas Creasey, 420051

EFFECTIVENESS OF AN ONLINE CONTINUING MEDICAL EDUCATION CURRICULUM TO IMPROVE HEMATOLOGISTS/ONCOLOGISTS’ ABILITY TO MANAGE MULTIPLE MYELOMA

EHA Library, Sarah Elizabeth Bomba, 420052

VALIDATION OF THE IMPEDE VTE SCORE FOR PREDICTION OF VENOUS THROMBOEMBOLISM IN CHINESE PATIENTS WITH MULTIPLE MYELOMA: A SINGLE-CENTER RETROSPECTIVE COHORT STUDY

EHA Library, Lijuan Fang, 420053

CARDIOVASCULAR TOXICITY AFTER CARFILZOMIB, LENALIDOMIDE, AND DEXAMETHASONE COMBINATION CHEMOTHERAPY IN THE REAL-WORLD ASIAN PATIENTS WITH RELAPSED AND REFRACTORY MULTIPLE MYELOMA

EHA Library, Ji Hyun Lee, 420054

IN-CLASS TRANSITION FROM PARENTERAL BORTEZOMIB (V) TO ORAL IXAZOMIB IN NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM): UPDATED ANALYSIS OF US MM-6 OVERALL AND BY PATIENT (PT) SUBGROUPS OF INTEREST

EHA Library, Ralph Boccia, 420056

MULTIPLE MYELOMA IN THE YOUNG: INSIGHTS ON PROGNOSIS, CLINICAL FEATURES AND TREATMENT OUTCOME DERIVED FROM NATIONALWIDE GERMAN REGISTRY DATA AND A NESTED MULTICENTER SAMPLE

EHA Library, Abdulaziz Kamili, 420059

UPDATED RESULTS OF A MATCHING-ADJUSTED INDIRECT COMPARISON OF ELRANATAMAB VERSUS TECLISTAMAB IN PATIENTS WITH TRIPLE-CLASS EXPOSED/REFRACTORY MULTIPLE MYELOMA

EHA Library, Patrick Hlavacek, 420064

OPERATIONAL CURE IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM) WHO UNDERWENT AUTOLOGOUS STEM CELL TRANSPLANT AS FIRST-LINE THERAPY AND  IMPACT OF INDUCTION REGIMENS

EHA Library, Jose Miguel Mateos Perez, 420067

REAL-WORLD TREATMENT PATTERNS, EFFICACY, AND SAFETY OF DARATUMUMAB-BASED REGIMENS IN CHINESE PATIENTS WITH MULTIPLE MYELOMA: AN UPDATED ANALYSIS OF THE MMY4032 STUDY

EHA Library, Luqun Wang, 420068

A PHASE 2 STUDY OF ISATUXIMAB IN COMBINATION WITH POMALIDOMIDE AND DEXAMETHASONE IN RRMM PATIENTS WITH 1 PRIOR LINE OF THERAPY

EHA Library, Evangelos Terpos, 420069

CLINICAL CHARACTERISTICS AND PROGNOSTIC ANALYSIS OF NON-AMYLOID MONOCLONAL GAMMOPATHY OF RENAL SIGNIFICANCE (MGRS) IN CHINA:  A LARGE-COHORT RETROSPECTIVE STUDY.

EHA Library, Yang Liu, 420071

EPIDEMIOLOGY AND REAL-WORLD MANAGEMENT OF MONOCLONAL GAMMOPATHIES PATIENTS IN SPAIN BASED ON NATURAL LANGUAGE PROCESSING AND MACHINE LEARNING TECHNIQUES, THE CIMMA STUDY

EHA Library, Joaquín Martínez-López, 420074

TREATMENT GOALS AND DECISION-MAKING CRITERIA FOR SECOND- AND THIRD-LINE THERAPY FOR MULTIPLE MYELOMA IN GERMANY

EHA Library, H Tilman Steinmetz, 420075

HYPOALBUMINEMIA, A NEW RISK FACTOR FOR PROGRESSION IN PATIENTS WITH MONOCLONAL GAMMOPATHY OF UNCERTAIN SIGNIFICANCE?

EHA Library, Elena Alejo, 420076

OUTCOMES IN PATIENTS WITH LIGHT CHAIN AMYLOIDOSIS AND RENAL INVOLVEMENT: FINDINGS FROM THE TRINETX DATABASE

EHA Library, Richa Manwani, 420077

WHAT CAN WE TELL OUR NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS WHO PRESENT WITH SEVERE RENAL INSUFFICIENCY REQUIRING DIALYSIS ABOUT RENAL RECOVERY? A CANADIAN SINGLE-CENTRE ANALYSIS

EHA Library, Rintu Sharma, 420078

CLINICAL EFFICACY OF ISATUXIMAB PLUS CARFILZOMIB -DEXAMETHASONE IN RELAPSED/REFRACTORY MULTIPLE MYELOMA PATIENTS: A REAL-LIFE MULTI-CENTER RETROSPECTIVE EXPERIENCE

EHA Library, Danilo De Novellis, 420079

OUTCOMES WITH SELINEXOR, BORTEZOMIB AND DEXAMETHASONE (SVD) IN PATIENTS WITH RELAPSED REFRACTORY MULTIPLE MYELOMA (RRMM): REGIONAL SUBGROUP ANALYSIS OF THE PHASE 3 BOSTON TRIAL

EHA Library, Andrew Spencer, 420080

CONTINUOUS THERAPY IN HHV-8 NEGATIVE MULTICENTRIC CASTLEMAN DISEASE: PIONEERING PROLONGED PROGRESSION-FREE SURVIVAL

EHA Library, Liangshun You, 420083

MINIMAL RESIDUAL DISEASE ASSESSMENT AND IMMUNE CORRELATES IN MULTIPLE MYELOMA THROUGH FLOW CYTOMETRY: A REAL-WORLD EXPERIENCE

EHA Library, Andrea Rizzuto, 420087

USING SERUM PROTEOMICS TO IDENTIFY FRAIL PATIENTS WITH MYELOMA

EHA Library, John Burthem, 420090

EVALUATION OF FACTORS ASSOCIATED WITH PROGRESSION FROM SMOLDERING MULTIPLE MYELOMA TO ACTIVE MULTIPLE MYELOMA

EHA Library, Elvira Umyarova, 420091

CLINICAL, HISTOPATHOLOGIC, AND ARTIFICIAL INTELLIGENCE (AI) EVALUATION OF MYELOPROLIFERATIVE NEOPLASM (MPN) DIAGNOSIS IN PATIENTS WITH MPN RELATED SPLANCHNIC VEIN THROMBOSIS (SVT)

EHA Library, Bharath Ram Sreedhar, 420093

EXPLORING PERCEPTIONS IN MANAGEMENT AND TREATMENT OF POLYCYTHAEMIA VERA (PV) IN THE UK: PV-PINPOINT STUDY

EHA Library, Mary Frances McMullin, 420099

RELATIONSHIP BETWEEN THE KITD816V ALLELE BURDEN AND MEDIATOR-RELATED SYMPTOMS EVALUATED WITH THE INDOLENT SYSTEMIC MASTOCYTOSIS SYMPTOM ASSESSMENT FORM (ISM-SAF)

EHA Library, Chiara Sartor, 420104

HYPOMETHYLATING AGENTS ARE EFFECTIVE IN TREATMENT FOR RELAPSED MYELOFIBROSIS AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION

EHA Library, Haris Ali, 420105

EASIX SCORE INDICATIVE OF ENDOTHELIAL DYSFUNCTION IS ASSOCIATED WITH HIGHER THROMBOTIC RISK AND IMPAIRED SURVIVAL IN PATIENTS WITH MYELOFIBROSIS

EHA Library, Marko Lucijanic, 420106

PROGNOSTIC POTENTIAL OF INFLAMMATORY BIOMARKERS IN PATIENTS WITH POLYCYTHEMIA VERA RECEIVING RUXOLITINIB: AN EXPLORATORY ANALYSIS OF RESPONSE, RESPONSE-2, AND PV-NIS

EHA Library, Francesca Palandri, 420107

ASSOCIATION BETWEEN HEMOGLOBIN IMPROVEMENT AND PATIENT-REPORTED OUTCOMES IN PATIENTS WITH MYELOFIBROSIS AND ANEMIA: POST HOC POOLED ANALYSIS OF MOMELOTINIB PHASE 3 TRIALS

EHA Library, Jeanne Palmer, 420108

HYPEREOSINOPHILIC DISORDERS: PRELIMINARY REAL-WORLD ANALYSIS BY PH-NEGATIVE MPN LATIAL GROUP

EHA Library, Caterina Tatarelli, 420109

EVALUATING MOLECULAR RISK FACTORS AND MUTATIONAL MODELS IN MYELOFIBROSIS AT A MULTI-ETHNIC INNER-CITY CENTER

EHA Library, John Yan, 420113

COMPARING THE EFFICACY AND SAFETY OF RUXOLITINIB IN PATIENTS WITH LOWER AND HIGHER RISK MYELOFIBROSIS: A SINGLE-ARM, EXPLORATORY AND PROSPECTIVE STUDY

EHA Library, Jian Huang, 420114

MYMPNVOICE – THE NEW MPN APP FOR PATIENT REPORTED OUTCOMES AND BIOMETRIC DATA MONITORING

EHA Library, Patrick Harrington, 420115

THE CLINICAL BURDEN OF MYELOFIBROSIS AND ASSOCIATED ANEMIA IN FRANCE

EHA Library, Alexander Slowley, 420116

VARIABLES ASSOCIATED WITH OUTCOMES IN PATIENTS WITH PHILADELPHIA CHROMOSOME-NEGATIVE MYELOPROLIFERATIVE NEOPLASM IN ACCELERATED PHASE/BLAST PHASE

EHA Library, Jiang Qian, 420117

EVALUATION OF THE RISKS OF DEVELOPING SECONDARY CANCERS IN PATIENTS WITH CHRONIC MYELOPROLIFERATIVE NEOPLASMS

EHA Library, Maria Kingsley-Godwin, 420118

PROSPECTIVE REAL-WORLD EVIDENCE OF BRENTUXIMAB VEDOTIN (BV) CONSOLIDATION AFTER AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION (ASCT) IN PATIENTS WITH RELAPSED/REFRACTORY HODGKIN LYMPHOMA (RR HL)

EHA Library, Astrid Pavlovsky, 420121

BCL-2-POSITIVE TUMOUR CELLS AS PREDICTORS OF THE COURSE OF NODULAR SCLEROSIS CLASSICAL HODGKIN LYMPHOMA

EHA Library, Dmitry Diakonov, 420123

A MODIFIED EORTC H10 (MH10)-BASED APPROACH IN PATIENTS WITH LIMITED-STAGE CLASSICAL HODGKIN LYMPHOMA (LS-CHL): SINGLE CENTER 6-YEAR EXPERIENCE WITH FOCUS TO YOUNGER PATIENTS

EHA Library, Theodoros Vassilakopoulos, 420124

BRENTUXIMAB VEDOTIN AND BENDAMUSTINE FOR RELAPSED HODGKIN LYMPHOMA: HIGH CMR RATE AND MANAGEABLE TOXICITY

EHA Library, Zin Aung Soe, 420128

REAL-WORLD ADHERENCE AND HEALTHCARE RESOURCE UTILIZATION OF BRUTON TYROSINE KINASE INHIBITORS (BTKI) IN MANTLE CELL LYMPHOMA

EHA Library, Bijal D. Shah, 420132

HIGH DOSE CHEMOTHERAPY AND AUTOLOGOUS STEM CELL TRANSPLANTATION AS SALVAGE TREATMENT FOR RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA IN THE RITUXIMAB ERA: A RETROSPECTIVE, SINGLE-CENTER ANALYSIS

EHA Library, Silvia Ferrari, 420133

SIGNIFICANCE STUDY OF PET/CT IMAGING EVALUATION IN MUCOSA-ASSOCIATED LYMPHOID TISSUE LYMPHOMA

EHA Library, Qingyang Zhang, 420135

THE RESULTS OF FRONTLINE INDUCTION IMMUNOCHEMOTHERAPY WITH R-GEMOX IN MANTLE CELL LYMPHOMA: A GOOD BALANCE BETWEEN EFFICACY AND SAFETY

EHA Library, Antonio Gutiérrez, 420136

RETROSPECTIVE ANALYSIS OF INFECTIOUS EVENTS IN LYMPHOMA PATIENTS WHO WERE TREATED WITH BENDAMUSTINE PLUS ANTI-CD20 MONOCLONAL ANTIBODY: KOREAN, MULTICENTER STUDY

EHA Library, Jun Ho Yi, 420137

FACTORS OF FAILURE OF THE MAIN 1ST-LINE IMMUNOCHEMOTHERAPY REGIMENS IN PATIENTS WITH FOLLICULAR LYMPHOMA: DATA FROM A TWO-CENTER STUDY

EHA Library, Evgenii Kunevich, 420139

REAL WORLD SAFETY AND EFFICACY DATA FOR USE OF RITUXIMAB AND BENDAMUSTINE (BR) IN TREATMENT OF ELDERLY AND OR UNFIT PATIENTS WITH MANTLE CELL LYMPHOMA

EHA Library, Sujeet Kumar, 420140

ESTABLISHING A ROBUST MOUSE MODEL FOR STUDYING MULTIPLE MYELOMA BONE DISEASE

EHA Library, Melika Bakharzi, 420039

MULTIPLE MYELOMA CAUSES CHANGES IN FATTY ACID METABOLISM IN TUMOUR ASSOCIATED MACROPHAGES VIA A FATP2 DEPENDENT MECHANISM

EHA Library, Rosie Taylor, 420041

REFRACTORY CYTOPENIAS AND SECONDARY MYELOID NEOPLASMS IN MULTIPLE MYELOMA AFTER AUTOLOGOUS STEM CELL TRANSPLANT AND LENALIDOMIDE MAINTENANCE THERAPY – A REAL-WORLD STUDY

EHA Library, David Martínez, 420042

IDENTIFYING IMMUNE CHECKPOINTS ON DYSREGULATED T-CELLS AS PROGNOSTIC BIOMARKERS FOR MULTIPLE MYELOMA PATIENTS WITH COVID-19

EHA Library, Junling Zhuang, 420045

THE ROLE OF BISPECIFIC ANTIBODIES AND CAR T CELLS IN THE TREATMENT OF MULTIPLE MYELOMA WITH CENTRAL NERVOUS SYSTEM INVOLVEMENT

EHA Library, Julia Mersi, 420046

REAL-WORLD CHARACTERISTICS AND OUTCOMES FOR LENALIDOMIDE-REFRACTORY PATIENTS WITH MULTIPLE MYELOMA RECEIVING DARATUMUMAB–BORTEZOMIB–DEXAMETHASONE AS SECOND-LINE TREATMENT IN ENGLAND

EHA Library, Sally Moore, 420048

EFFECT OF DENOSUMAB ON PROGRESSION-FREE SURVIVAL AND BONE HEALTH IN PATIENTS WITH MULTIPLE MYELOMA: A MULTICENTER PROSPECTIVE OBSERVATIONAL STUDY

EHA Library, Bin Chu, 420049

COULD CLINICAL-LABORATORY FEATURES RECOGNIZE FUNCTIONAL HIGH RISK MULTIPLE MYELOMA PATIENTS? A REAL-WORLD ANALYSIS

EHA Library, Sonia Morè, 420055

INDIRECT TREATMENT COMPARISONS OF DARATUMUMAB-POMALIDOMIDE-DEXAMETHASONE (DPD) AND POMALIDOMIDE-BORTEZOMIB-DEXAMETHASONE (PVD) IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM)

EHA Library, Wee Joo Chng, 420057

REAL WORLD ASSESSMENT: EARLY BEST RESPONSE AS A HARBINGER OF POOR PROGNOSIS IN NEWLY DIAGNOSIS MULTIPLE MYELOMA IN THE ERA OF NOVEL AGENTS

EHA Library, Ning Liu, 420058

REAL-WORLD OBSERVATIONS ON THE EVOLVING TREATMENT LANDSCAPE AND IMPROVED SURVIVAL OUTCOMES FOR MULTIPLE MYELOMA PATIENTS IN FINLAND

EHA Library, Marika Waltari, 420060

THE VALUE OF PERIPHERAL BLOOD LYMPHOCYTE SUBSETS IN PREDICTING THE PROGNOSIS OF NEWLY DIAGNOSED MULTIPLE MYELOMA

EHA Library, Zhaoyun Liu, 420061

ZANUBRUTINIB IN MONOCLONAL IMMUNOGLOBULIN M-RELATED LIGHT CHAIN AMYLOIDOSIS: TOLERABILITY AND EFFICACY

EHA Library, Wouter Verhaar, 420062

PATIENT-REPORTED OUTCOMES FROM THE RANDOMIZED PHASE 3 CANOVA STUDY OF VENETOCLAX-DEXAMETHASONE VS POMALIDOMIDE-DEXAMETHASONE IN PATIENTS WITH T(11;14)-POSITIVE RELAPSED/REFRACTORY MULTIPLE MYELOMA

EHA Library, María-Victoria Mateos, 420065

INDIRECT COMPARISON OF LINVOSELTAMAB VERSUS TECLISTAMAB FOR TRIPLE-CLASS EXPOSED RELAPSED/REFRACTORY MULTIPLE MYELOMA

EHA Library, Hans Lee, 420066

A COMPARISON OF PATIENT-REPORTED PERIPHERAL NEUROPATHY AMONG PATIENTS TREATED WITH ELRANATAMAB VERSUS REAL WORLD CLINICAL PRACTICE IN TRIPLE-CLASS REFRACTORY MULTIPLE MYELOMA

EHA Library, Paula Rodríguez-Otero, 420070

LONGITUDINAL ASSESSMENT OF CONTEMPORARY RISK STRATIFICATION MODELS IN PATIENTS WITH MONOCLONAL GAMMOPATHY OF UNDETERMINED SIGNIFICANCE

EHA Library, Kosima Zuern, 420072

EFFICACY AND SAFETY OF IXAZOMIB-BASED SALVAGE THERAPIES IN MULTIPLE MYELOMA PATIENTS WITH A PRIOR HISTORY OF BORTEZOMIB-INDUCED PERIPHERAL NEUROPATHY

EHA Library, Xiang Zhou, 420073

IGH GENE REARRANGEMENT PATTERNS OBSERVED WITH THE USE OF FLUORESCENCE IN SITU HYBRIDIZATION (FISH) IN MULTIPLE MYELOMA PATIENTS

EHA Library, Natalia Tsybakova, 420081

EXTRAMEDULLARY DISEASE IN MULTIPLE MYELOMA: CLINICOBIOLOGICAL CHARACTERISTICS AND PROGNOSTIC IMPACT

EHA Library, Aleksandra Sretenovic, 420082

SECONDARY RESISTANCE MECHANISMS AFTER BCMA-TARGETING THERAPIES IN MULTIPLE MYELOMA:  WHOLE-GENOME SEQUENCING AND IN SILICO STRUCTURAL MODELING IDENTIFIES NOVEL TNFRSF17 MUTATIONS

EHA Library, Ricardo Kosch, 420084

IXAZOMIB, POMALIDOMIDE AND DEXAMETHASONE (IXAPD) PAN-ORAL REGIMEN IN THE TREATMENT OF REFRACTORY AND RELAPSED MULTIPLE MYELOMA

EHA Library, Miao Chen, 420085

PROGNOSTIC SIGNIFICANCE OF COMPOSITE HEMATOLOGIC AND ORGAN RESPONSE (CHOR) IN NEWLY DIAGNOSED PATIENTS WITH LIGHT-CHAIN AMYLOIDOSIS.

EHA Library, Marko Mitrovic, 420086

CARFIL-HAD PILOT STUDY: SECURE OUTSOURCING IN HOSPITALIZATION AT HOME (HAH) OF CARFILZOMIB IN MULTIPLE MYELOMA TREATMENT. CARE MODEL ORGANIZATION FOR SHORT-DURATION INTRAVENOUS CHEMOTHERAPIES AT HOME

EHA Library, Mohamed Touati, 420088

COMPARING CYTOGENETIC ABNORMALITIES IN NEWLY DIAGNOSED MULTIPLE MYELOMA BETWEEN AFRICAN AMERICAN AND NON-AFRICAN AMERICAN PATIENTS USING CHROMOSOME MICROARRAY ANALYSIS

EHA Library, Matthew Hamby, 420089

ROLE OF RED CELL MASS EVALUATION IN MYELOPROLIFERATIVE NEOPLASMS WITH SPLANCHNIC VEIN THROMBOSIS AND NORMAL HEMOGLOBIN VALUE: A STUDY OF THE FRANCE INTERGROUPE DES SYNDROMES MYELOPROLIFÉRATIFS.

EHA Library, Jean Galtier, 420092

COMPREHENSIVE ANALYSIS OF DIAGNOSIS, TREATMENT AND OUTCOME IN A RETROSPECTIVE COHORT OF HES PATIENTS IN THE SOUTH-WEST OF THE NETHERLANDS BETWEEN 2000-2020.

EHA Library, Pim Mutsaers, 420094

PATIENT JOURNEY TO DIAGNOSIS AND TREATMENT OF HYPEREOSINOPHILIC SYNDROME IN EUROPE AND THE UNITED STATES: EVIDENCE FROM A REAL-WORLD SURVEY IN CLINICAL PRACTICE

EHA Library, Priya Jain, 420095

MOMELOTINIB MANAGED ACCESS PROGRAM FOR PATIENTS WITH MYELOFIBROSIS: BASELINE CHARACTERISTICS IN THE UK, ITALY, GREECE, AUSTRIA, AND BELGIUM

EHA Library, Claire Harrison, 420096

RUXOLITINIB IMPROVED SURVIVAL IN MYELOFIBROSIS PATIENTS WITH 1 OR MORE HIGH MOLECULAR RISK  MUTATIONS

EHA Library, Chun Teh, 420097

ACCELERATED IMMUNE EFFECTOR CELL RECONSTITUTION IN MYELOFIBROSIS PATIENTS TREATED WITH MOMELOTINIB AFTER RUXOLITINIB

EHA Library, Jasmine Makker, 420098

SEVERE ANEMIA AND CO-OCCURRENCE OF ANEMIA AND THROMBOCYTOPENIA IDENTIFY VERY HIGH-RISK PMF PATIENTS

EHA Library, Paola Guglielmelli, 420100

IMPACT OF ATRIAL FIBRILLATION ON THROMBOTIC COMPLICATIONS IN MPN PH-NEG PATIENTS: REAL-LIFE ANALYSIS

EHA Library, Olga Chyrko, 420101

MITIGATION OF ATRIAL FIBRILLATION-RELATED COMPLICATIONS WITH  COMBINED ANTITHROMBOTIC AND CYTOREDUCTIVE THERAPY IN PATIENTS WITH MYELOPROLIFERATIVE NEOPLASMS

EHA Library, Hyunyee Rosa Cho, 420102

LONG-TERM OUTCOME AND PROGNOSIS OF 69 PATIENTS WITH MIXED HISTIOCYTOSIS

EHA Library, Francesco Pegoraro, 420103

CAUSE-SPECIFIC MORTALITY TRENDS IN MYELOPROLIFERATIVE NEOPLASMS ACROSS DEMOGRAPHIC GROUPS: A RETROSPECTIVE COHORT STUDY

EHA Library, Muhammad Ali Khan, 420110

PROGNOSTIC NUTRITIONAL INDEX (PNI) AT DIAGNOSIS PREDICTS OUTCOME IN PATIENTS WITH PRIMARY MYELOFIBROSIS: A MONOCENTRIC REAL-LIFE STUDY

EHA Library, Veronica Guglielmana, 420111

A RETROSPECTIVE ANALYSIS OF PACRITINIB TREATMENT OUTCOMES IN MYELOFIBROSIS PATIENTS WITH AND WITHOUT MONOCYTOSIS

EHA Library, John Mascarenhas, 420119

HEALTH-RELATED QUALITY OF LIFE IN ITALIAN PATIENTS WITH PHILADELPHIA-NEGATIVE MYELOPROLIFERATIVE NEOPLASMS COMPARED TO THE GENERAL POPULATION: GIMEMA PROPHECY STUDY

EHA Library, Giovanni Caocci, 420120

ANTI-TIM-3 ANTIBODY TQB2618 IN COMBINATION WITH PENPULIMAB IN RELAPSED OR REFRACTORY CLASSIC HODGKIN LYMPHOMA PREVIOUSLY TREATED WITH PD-1/PD-L1 THERAPY

EHA Library, Tongyu Lin, 420122

PREDICTIVE FACTORS OF AUTOLOGOUS STEM CELL TRANSPLANTATION OUTCOMES AFTER ANTI-PD-1 TREATMENT IN PATIENTS WITH RELAPSED/REFRACTORY CLASSICAL HODGKIN LYMPHOMA

EHA Library, Nikita Mochkin, 420125

COFORMULATED VIBOSTOLIMAB/PEMBROLIZUMAB IN RELAPSED/REFRACTORY CHL AND PMBCL: AN ANALYSIS OF COHORTS A AND B OF THE KEYVIBE-004 STUDY

EHA Library, David Lavie, 420126

SAFETY, PHARMACOKINETICS, PHARMACODYNAMICS AND CLINICAL ACTIVITY OF KT-333, A TARGETED PROTEIN DEGRADER OF STAT3, IN PATIENTS WITH RELAPSED OR REFRACTORY HEMATOLOGIC AND SOLID TUMOR CANCERS

EHA Library, Aditi Shastri, 420127

BRENTUXIMAB VEDOTIN IN COMBINATION WITH BEGEV IN PATIENTS WITH RELAPSED OR REFRACTORY HODGKIN'S LYMPHOMA: 3-YEAR FOLLOW-UP.

EHA Library, Matvey Bulusov, 420129

CHANGES IN SURVIVAL OF PATIENTS WITH HODGKIN'S LYMPHOMA OVER THE LAST FOUR DECADES

EHA Library, Zsófia Miltényi, 420130

ODRONEXTAMAB MONOTHERAPY FOR RELAPSED/REFRACTORY (R/R) FOLLICULAR LYMPHOMA (FL) AND DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL): CLINICAL PHARMACOLOGY AND PHARMACOMETRICS IN THE ELM-1 AND ELM-2 STUDIES

EHA Library, Raul Cordoba, 420131

MINIMAL RESIDUAL DISEASE MONITORING IN PATIENTS WITH FOLLICULAR LYMPHOMA AFTER HIGH-DOSE CHEMOTHERAPY AND AUTOLOGOUS HAEMATOPOIETIC STEM CELL TRANSPLANTATION: RESULT FROM FL-015 TRIAL.

EHA Library, Anna Smolyaninova, 420134

THE CLINICAL CHARACTERISTICS AND PROGNOSIS OF FOLLICULAR LYMPHOMA GRADE 3A

EHA Library, Wenjuan Yu, 420138